Log in
Enquire now
‌

US Patent 11639529 EML4-ALK translocations in lung cancer

Patent 11639529 was granted and assigned to Quest Diagnostics on May, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Quest Diagnostics
Quest Diagnostics
0
Current Assignee
Quest Diagnostics
Quest Diagnostics
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
116395290
Patent Inventor Names
Maher Albitar0
Aurelia Meloni-Ehrig0
Heather R. Sanders0
Date of Patent
May 2, 2023
0
Patent Application Number
165947180
Date Filed
October 7, 2019
0
Patent Citations
‌
US Patent 10435758 EML4-ALK translocations in lung cancer
0
Patent Primary Examiner
‌
Carla J. Myers
0

The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11639529 EML4-ALK translocations in lung cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.